ScreenerHero

EBS Emergent BioSolutions Inc.

NYSE · US · Healthcare · Drug Manufacturers - Specialty & Generic · emergentbiosolutions.com
7.070USD+1.73%Mkt Cap: 362.50M $P/E: —

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationall…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap362.50M USD
Enterprise Value804.85M USD
Revenue (TTM)770.20M USD
Gross Profit379.00M USD
Net Income (TTM)52.60M USD
Revenue/Share14.76 USD
Last Price7.070 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees900
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)6.64
PEG0.38
EV/EBITDA3.43
EV/Revenue1.04
P/S0.46
P/B1.04
EPS (TTM)-3.40
EPS (Forward)1.05
52W Range
4.36528% of range14.06
52W High14.06 USD
52W Low4.365 USD
Profitability
Gross Margin53.74%
Oper. Margin28.34%
EBITDA Margin30.50%
Profit Margin7.46%
ROE10.07%
ROA3.99%
Growth
Revenue Growth66.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF170.60M USD
CapEx (TTM)13.80M USD
FCF Margin5.19%
FCF Yield11.03%
Net Debt448.50M USD
Net Debt/EBITDA1.91
Balance Sheet
Debt/Equity1.09
Current Ratio5.42
Quick Ratio2.69
Book Value/Sh6.66 USD
Cash/Share2.73 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)11.00 USD
Upside (mean)+55.6%
Target Range10.00 USD – 12.00 USD
10.00+55.6% to mean12.00
# Analysts2
Ownership
Shares Out.51.27M
Float49.07M
Insiders4.25%
Institutions90.66%
Short Interest
Short Ratio8.4d
Short % Float19.39%
Short % Out.19.09%
Shares Short9.79M
Short (prev mo.)11.64M
Technical
SMA 506.121 (+15.5%)
SMA 2008.548 (-17.3%)
Beta2.29
S&P 52W Chg16.45%
Avg Vol (30d)1.18M
Avg Vol (10d)1.04M
Technical Indicators
RSI (14)58.4
MACD0.1835
MACD Signal0.1555
MACD Hist.+0.0280
BB Upper7.326 USD
BB Middle6.665 USD
BB Lower6.003 USD
BB Width19.85%
ATR (14)0.4083 USD
Vol Ratio (20d)1.01x